Maxim initiated coverage of Nuvectis Pharma (NVCT) with a Buy rating and $17 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCT:
- Nuvectis Pharma initiated with a Buy at Laidlaw
- Nuvectis announces new publication of research study on NXP900, osimertinib
- Nuvectis Pharma Reports 2024 Financial Results and Progress
- Nuvectis Pharma initiated with a Buy at Lucid Capital
- Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue